* Cell Therapeutics Inc., of Seattle, said a double-blindedpilot study of lisofylline showed the small moleculecompound may be effective in treating acute respiratorydistress syndrome (ARDS). Lisofylline is designed toinhibit production of phosphatidic acid and reduceoxidative damage to the lungs and other organs affectedby ARDS.
* Zonagen Inc., of The Woodlands, Tx., completed a saleof 598,850 shares of convertible preferred stock for $5.5million in net proceeds. Each preferred share isconvertible at any time into 2.758 common shares.
* Targeted Genetics Corp., of Seattle, began a genetherapy trial for treatment of Gaucher's disease. Thestudy involves using a retroviral vector to transfer ex vivoa glucocerebrosidase (GC) gene into patients' purifiedstem cells, which are then re-infused. The trial willevaluate the safety of the procedure and determinewhether the GC gene is reproduced in the patients.Gaucher's disease is caused by a missing GC gene. Thestudy will be conducted at the Fred Hutchinson CancerResearch Center in Seattle in conjunction with CellProInc., of Seattle, which makes cell separation systems.
* Cytogen Corp., of Princeton, N.J., completed itsacquisition of Cellcor Inc., of Newton, Mass., in a swapof stock valued at about $19 million.
* IDEC Pharmaceuticals Corp., of San Diego, said itsPhase I/II dose-escalating trials of anti-CD4 monoclonalantibody, IDEC-CE9.1, showed 20 of 40 patients withmoderate to severe rheumatoid arthritis experienced"clinically significant" reductions in signs and symptoms.The company, which is developing the drug inassociation with London-based SmithKline Beecham plc,said based on the data it began a placebo-controlled PhaseII study.
(c) 1997 American Health Consultants. All rights reserved.